AVITA Medical (RCEL) risk factors, FY2024 10-K

Risks Related to Our Business Operations

1. 01We have experienced significant losses, expect losses to continue for the foreseeable future and may never achieve or maintain profitability
2. 02Servicing our debt requires a significant amount of cash and we are subject to a number of restrictive covenants relating to our indebtedness, which may restrict our business and financing activities
3. 03We may require additional financing in the future to continue the development and commercialization of our RECELL System or any future products, which may cause dilution to our existing stockholders. If additional financing is not available, we may have to postpone, reduce or cease operations
4. 04The markets in which we operate are highly competitive and innovative. Our competitors may develop products that render our products less attractive or obsolete and our business may deteriorate
5. 05Our success depends, in part, on our relationships with, and the efforts of, third-party distributors
6. 06We may be unsuccessful in commercializing our RECELL System or other future products due to unfavorable pricing regulations or third-party coverage or reimbursement policies
7. 07CPT codes that describe “skin cell suspension autograft to support physician reimbursement by professional healthcare services and for facility services at ambulatory surgical centers (“ASCs”), and Ambulatory Payment Classifications (“APCs”) for hospital reimbursement for outpatient department services
8. 08Certain of our products are dependent on specialized sources of supply potentially subject to disruption which could have a material, adverse impact on our business
9. 09We may encounter substantial delays in further clinical studies necessary to support regulatory applications for additional commercial applications of our technology
10. 10A failure in a clinical study or regulatory application can occur at any stage. Events that may prevent successful or timely
11. 11disagreements with regulatory agencies in the interpretation of the data from our clinical trials
12. 12Product development is an expensive, uncertain and lengthy process
13. 13Development and commercialization of our products require successful completion of the regulatory approval process and may suffer delays or fail
14. 14We are highly dependent on our regulatory approval in the United States and failure to maintain that approval would materially impact our business and prospects
15. 15Obtaining and maintaining regulatory approval for a product in one jurisdiction does not mean that we will be successful in obtaining regulatory approval for that product in other jurisdictions
16. 16Product recalls or inventory losses caused by unforeseen events may adversely affect our operating results and financial condition
17. 17We face manufacturing risks that may adversely affect our ability to manufacture products and could reduce our gross margins and negatively affect our business and operating results
18. 18inability to increase production capacity or volumes to meet demand
19. 19Compliance with environmental, health and safety requirements is costly and, if not achieved, could result in material financial fines, costly litigation, and a material adverse impact on the business
20. 20We may be subject to civil fines and/or criminal penalties if the FDA determines that we have marketed or promoted our products for off-label usage
21. 21We rely on information technology systems for critical business functions and the operations of our business
22. 22A cyber security incident could be disruptive to our business, compromise confidential data, cause reputation harm, and subject us to litigation and federal and state governmental inquiries

Risks Relating to our Industry and Technology

1. 23We face competition from the existing standard of care and any future potential changes in medical practice and technology and the possibility that our competitors may develop products, treatments or procedures that are similar, more advanced, safer or more effective than ours
2. 24If we are unable to effectively protect our intellectual property, we may not be able to operate our business and third parties may be able to use and profit from our technology, both of which would impair our ability to be competitive
3. 25We may find it difficult to protect our intellectual property rights throughout the world
4. 26If third parties make claims of intellectual property infringement against us, or otherwise seek to establish their intellectual property rights equal or superior to ours, we may have to spend time and money in response and potentially discontinue certain of our operations
5. 27We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights and we may be unable to protect our rights to, or use of, our technology
6. 28We could be subject to product liability lawsuits, which could result in costly and time-consuming litigation and significant liabilities
7. 29The continued successful commercialization of the RECELL System for FDA approved and pending indications, will depend in part on the extent to which government authorities and healthcare insurers establish adequate reimbursement levels and pricing policies
8. 30Our current and future relationships with regulators, HCPs, third-party payors, customers, and consultants will be subject to applicable healthcare laws and regulations, as well as to other laws and regulations addressing fraud and abuse, and failure to comply with such laws could expose us to penalties
9. 31Data/Privacy Protection: a number of federal, state and foreign laws, regulations, guidance and standards that impose requirements regarding the protection of consumer information that are applicable to or affect our operations

Macroeconomic and Social Risks

1. 32Adverse changes in general economic conditions or uncertainty about future economic conditions, could adversely affect us

Risks Relating to Our Common Stock and CDIs

1. 33We have never paid a dividend on our common stock and CDIs and do not intend to do so in the foreseeable future, and consequently, investors’ only opportunity to realize a return on their investment in the Company is through the appreciation in the price of our common stock and CDIs
2. 34Our equity issuances will be limited by ASX Listing Rule 7.1 so long as we continue to be listed on the ASX and this constraint may prevent us from raising the full amount of equity capital needed for operations without prior stockholder approval
3. 35There has been relatively limited trading volume in the markets for our common stock and CDIs, and more active, liquid trading markets for such securities may never develop
4. 36The market price and trading volume of our common stock and CDIs may be volatile and may be affected by variability in our performance from period to period and economic conditions beyond management’s control
5. 37If research analysts publish unfavorable commentary or downgrade our common stock or CDIs, it could adversely affect our share price and trading volume
6. 38The requirements of being a public company in the United States and listed on the ASX may strain our resources and divert management’s attention
7. 39We are an emerging growth company, and the reduced disclosure requirements applicable to emerging growth companies may make our common stock less attractive to investors
8. 40The Company's cash, cash equivalents and marketable securities could be adversely affected by bank failures or other events affecting financial institutions and could adversely affect our liquidity and financial performance
9. 41If we fail to manage our growth effectively, our business could be disrupted
10. 42Our growth and success depend on our ability to attract and retain additional highly qualified and skilled sales and marketing, research and development, operational, managerial, legal, and finance personnel